← Back to Clinical Trials
Recruiting NCT06427564

NCT06427564 Vital Signs Collection Via "Comestai" App

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06427564
Status Recruiting
Phase
Sponsor Buzzi Children's Hospital
Condition Vital Signs
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2024-06-01
Primary Completion 2025-12-01

Eligibility & Interventions

Sex All sexes
Min Age 16 Years
Max Age 65 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 2024-06-01 with a primary completion date of 2025-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of the study is to verify and validate the parameters collected from mobile devices via the app named "Comestai" and from reference devices. The assessments considered to define comorbidities are included.. Specifically, collection of vital parameters (Blood Pressure, Heart Rate, Respiratory Rate, Oxygen Saturation) through the "Comestai" Application via mobile phones (using photoplethysmographic method) and reference devices such as Withings-Blood Pressure Monitor Connect® (for Blood Pressure), Polar Verity Sense® (for Heart Rate), Masimo-finger sensor® (for Oxygen Saturation, Respiratory Rate), comparing and confirming them. Consent will be sought for the viewing and collection of blood test results that are normally included in evaluations for subjects with overweight and/or obesity and/or diabetes. Estimated time required for each measurement recording: 10-15 minutes per subject Total number of subjects: 3000

Eligibility Criteria

Inclusion Criteria: Prior to enrollment in this study, subjects must meet all the following inclusion criteria: 1. Subject must have the ability to understand and provide written informed consent. 2. Male or Female subject ≥16 and ≤65 of age. 3. Subject must be willing and able to comply with study procedures. Exclusion Criteria: Subjects will be excluded from the study if any of the following conditions are present: 1. Subject with compromised circulation, injury, or physical malformation of fingers, hands, ears or forehead/skull or other sensor Region of Interest (ROI) which would limit the ability to test ROI needed for the study. 2. Subject has a tattoo in the optical path which would limit the ability to test ROI needed for the study. 3. Subjects with severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, respiration monitor electrodes or other medical sensors used for measuring vital signs. 4. Subject with a medical condition which in the opinion of the investigator, does not allow performing the study assessments. 5. Subject unfit to participate in the study to the judgment of the investigator. In addition to the Inclusion/Exclusion criteria, the 70% of target population should include adult subjects with at least one of the following: * Pre-diabetes or diabetes HbA1C 5.7-13% * \>30% of subjects with HbA1C 5.7-6.4% * \>30% of subjects with HbA1C \>6.4% * Hypertension with systolic measurements above 130 mmHg * \>40% of subjects with systolic BP \>130 mmHg * \>20% of subjects with systolic BP \>160 mmHg * Total cholesterol: \>40% of subjects with \>200 mg/dl and/or LDL above 130 mg/dl * Atrial fibrillation 1% * Smokers \~ 20-30% of all subjects in the study Note: the same subject can have more than one of the above medical conditions. It is preferred that subjects will be treatment- naive for the medical condition they suffer from or are not under treatment at the time of participation (e.g. a subject who suffers from hypertension has not started his treatment to lower his blood pressure).

Contact & Investigator

Central Contact

Gianvincenzo Zuccotti, MD, Prof

✉ gianvincenzo.zuccotti@unimi.it

📞 +390263631

Principal Investigator

Gianvincenzo Zuccotti, MD, Prof

PRINCIPAL INVESTIGATOR

Buzzi Children's Hospital

Frequently Asked Questions

Who can join the NCT06427564 clinical trial?

This trial is open to participants of all sexes, aged 16 Years or older, up to 65 Years, studying Vital Signs. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06427564 currently recruiting?

Yes, NCT06427564 is actively recruiting participants. Contact the research team at gianvincenzo.zuccotti@unimi.it for enrollment information.

Where is the NCT06427564 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT06427564 clinical trial?

NCT06427564 is sponsored by Buzzi Children's Hospital. The principal investigator is Gianvincenzo Zuccotti, MD, Prof at Buzzi Children's Hospital. The trial plans to enroll 3,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology